Patterns of transmitted HIV drug resistance in europe vary by risk group
Frentz D, Van De Vijver D, Abecasis A, Albert J, Hamouda O, Jorgensen L, Kucherer C, Struck D, Schmit JC, Vercauteren J, Asjo B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KLM, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stoeckl E, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher C, Wensing A (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Book Volume: 9
Pages Range: e94495
Journal Issue: 4
DOI: 10.1371/journal.pone.0094495
Abstract
In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression.From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively).MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.
Involved external institutions
University Medical Centre Utrecht (UMC Utrecht)
Netherlands (NL)
Erasmus University Medical Center (MC)
Netherlands (NL)
Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven
Belgium (BE)
University of Belgrade / Универзитет у Београду
Serbia (RS)
Slovak Medical University (SMU) / Slovenská zdravotnícka univerzita v Bratislave
Slovakia (SK)
Karolinska University Hospital / Karolinska Universitetssjukhuset
Sweden (SE)
Medizinische Universität Wien
Austria (AT)
University of Ljubljana (UL) / Univerza v Ljubljani
Slovenia (SI)
Medical University Sofia / Медицински университет
Bulgaria (BG)
National and Kapodistrian University of Athens
Greece (GR)
Institute for Infectious Diseases 'Matei Bals' (IDMB) / Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"
Romania (RO)
Robert Koch-Institut (RKI)
Germany (DE)
National Institute for Health and Welfare (THL)
Finland (FI)
Luxembourg Institute of Health (CRP-Santé)
Luxembourg (LU)
St. James's Hospital
Ireland (IE)
Università degli studi di Milano
Italy (IT)
University of Bergen / Universitetet i Bergen
Norway (NO)
Statens Serum Institut
Denmark (DK)
Karolinska Institute
Sweden (SE)
New University of Lisbon / Universidade Nova de Lisboa
Portugal (PT)
Hospital Universitari Germans Trias i Pujol
Spain (ES)
Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר
Israel (IL)
University of Cyprus (UCY) / Πανεπιστήμιο Κύπρου
Cyprus (CY)
Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu
Poland (PL)
National Public Health Surveillance Laboratory of Lithuania Respublic
Lithuania (LT)
Netherlands (NL)
Erasmus University Medical Center (MC)
Netherlands (NL)
Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven
Belgium (BE)
University of Belgrade / Универзитет у Београду
Serbia (RS)
Slovak Medical University (SMU) / Slovenská zdravotnícka univerzita v Bratislave
Slovakia (SK)
Karolinska University Hospital / Karolinska Universitetssjukhuset
Sweden (SE)
Medizinische Universität Wien
Austria (AT)
University of Ljubljana (UL) / Univerza v Ljubljani
Slovenia (SI)
Medical University Sofia / Медицински университет
Bulgaria (BG)
National and Kapodistrian University of Athens
Greece (GR)
Institute for Infectious Diseases 'Matei Bals' (IDMB) / Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"
Romania (RO)
Robert Koch-Institut (RKI)
Germany (DE)
National Institute for Health and Welfare (THL)
Finland (FI)
Luxembourg Institute of Health (CRP-Santé)
Luxembourg (LU)
St. James's Hospital
Ireland (IE)
Università degli studi di Milano
Italy (IT)
University of Bergen / Universitetet i Bergen
Norway (NO)
Statens Serum Institut
Denmark (DK)
Karolinska Institute
Sweden (SE)
New University of Lisbon / Universidade Nova de Lisboa
Portugal (PT)
Hospital Universitari Germans Trias i Pujol
Spain (ES)
Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר
Israel (IL)
University of Cyprus (UCY) / Πανεπιστήμιο Κύπρου
Cyprus (CY)
Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu
Poland (PL)
National Public Health Surveillance Laboratory of Lithuania Respublic
Lithuania (LT)
How to cite
APA:
Frentz, D., Van De Vijver, D., Abecasis, A., Albert, J., Hamouda, O., Jorgensen, L.,... Wensing, A. (2014). Patterns of transmitted HIV drug resistance in europe vary by risk group. PLoS ONE, 9(4), e94495. https://doi.org/10.1371/journal.pone.0094495
MLA:
Frentz, Dineke, et al. "Patterns of transmitted HIV drug resistance in europe vary by risk group." PLoS ONE 9.4 (2014): e94495.
BibTeX: Download